Lexeo links gene therapy to improvements in rare heart disease but disappoints investors

[cafead]

via Lexeo Therapeutics has guided its Friedreich ataxia (FA) gene therapy through an early test, generating evidence of improvements in cardiac status in early-phase trials. But the biotech ran into problems when testing the effect of the candidate on fitness and was left with a gap in evidence.

article source